Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population‐based testing program. Issue 1 (22nd October 2020)

• Record Type: Journal Article
• Authors: Care, Melanie; McCuaig, Jeanna; Clarke, Blaise; Grenier, Sylvie; Kim, Raymond H; Rouzbahman, Marjan; Stickle, Natalie; Bernardini, Marcus; Stockley, Tracy L.
• Is Part Of: Molecular oncology. Volume 15:Issue 1(2021)
• Page Start: 80
• Page End: 90
• Publication Date: 2020-10-22
• Subjects: BRCA1/BRCA2 -- germline variant -- high‐grade serous cancer -- next‐generation sequencing -- somatic variant -- tumor testing; Cancer -- Molecular aspects -- Periodicals; 616.994005
• DOI: 10.1002/1878-0261.12817
• Languages: English
• ISSNs: 1574-7891

Abstract

Abstract : The aim of this study was to determine the prevalence of somatic and germline pathogenic variants (PVs) in high‐grade serous cancer (HGSC) and to demonstrate the technical feasibility and effectiveness of a large‐scale, population‐based tumor testing program. It involved a retrospective review of genetic test results in 600 consecutive HGSC tumor samples and a subsequent comparison of germline and tumor results in a subset of 200 individuals. Tumor testing was successful in 95% of samples (570/600) with at least one BRCA1/2 PV identified in 16% (93/570) of cases. Among the 200 paired cases, BRCA1/2 PVs were detected in 38 tumors (19%); 58% were somatic (22/38); and 42% were germline (16/38). There was 100% concordance between germline and tumor test results. This is the largest series of BRCA1/2 testing in HGSC (tumor‐only and paired cohorts), reported to date, and our data show that an effectively designed and validated population‐based tumor testing program can be used to determine both treatment eligibility and hereditary cancer risk. Abstract : The presence of somatic or germline BRCA1/2 pathogenic variants impacts the effectiveness of PARP inhibitor therapy in high‐grade serous ovarian cancer. This study demonstrates that a large‐scale tumor testing program can effectively and accurately identify both germline and somatic variants. Nearly 60% of pathogenic variants are somatic, emphasizing the importance of tumor testing in care pathways of this patient population.